[1] Dostert C,Pétrilli V,Van Bruggen R,et al.Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica[J].Science,2008,320(5876):674-677.
[2] Medzhitov R.Approaching the asymptote:20 years later[J].Immunity,2009,30(6):766-775.
[3] Iwasaki A,Medzhitov R.Toll-like receptor control of the adaptive immune responses[J].Nat Immunol,2009,5(10):987-995.
[4] Brown GD.Dectin-1:a signalling non-TLR pattern-recognition receptor[J].Nat Rev Immunol,2006,6(1):33-43.
[5] Akira S,Takeda K.Toll-like receptor signalling[J].Nat Rev Immunol,4(7):499-511.
[6] Gazi U,Rosas M,Singh S,et al.Fungal recognition enhances mannose receptor shedding through dectin-1 engagement[J].J Biol Chem,2011,286(10):7822-7829.
[7] Akira S,Uematsu S,Takeuchi O.Pathogen recognition and innate immunity[J].Cell,2006,124(4):783-801.
[8] Shoham S,Huang C,Chen JM,et al.Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule[J].J Immunol,2001,166(7):4620-4626.
[9] Mansour MK,Latz E,Levitz SM.Cryptococcus neoformans glycoantigens are captured by multiple lectin receptors and presented by dendritic cells[J].J Immunol,2006,176:(5)3053-3061.
[10] Giles SS,Dagenais TR,Botts MR,et al.Elucidating the pathogenesis of spores from the human fungal pathogen Cryptococcus neoformans[J].Infect Immun,2009,77(8):3491-3500.
[11] Guo C,Chen M,Fa Z,et al. Acapsular Cryptococcus neoformans activates the NLRP3 inflammasome[J].Microbes Infect,2014,16(10):845-854.
[12] Kelly RM,Chen J,Yauch LE,et al.Opsonic requirements for dendritic cell-mediated responses to Cryptococcus neoformans[J].Infect Immun,2005,73(1):592-598.
[13] Davis MJ,Eastman AJ,Qiu Y,et al.Cryptococcus neoformans-Induced macrophage lysosome damage crucially contributes to fungal virulence[J].J Immunol,2015,194:(5)2219-2231.
[14] Velagapudi R,Hsueh YP,Geunes-Boyer S,et al.Spores as infectious propagules of Cryptococcus neoformans[J].Infect Immun,2009,77(10):4345-4355.
[15] Dromer F,Ronin O,Dupont B.Isolation of Cryptococcus neoformans var.gattii from an Asian patient in France:evidence for dormant infection in healthy subjects[J].J Med Vet Mycol,1992,30(5):395-397.
[16] Garcia-Hermoso D,Janbon G,Dromer F.Epidemiological evidence for dormant Cryptococcus neoformans infection[J].J Clin Microbiol,1999,37(10):3204-3209.
[17] Singh N,Alexander BD,Lortholary O,et al.Pulmonary cryptococcosis in solid organ transplant recipients:Clinical relevance of serum cryptococcal antigen[J].Clin Infect Dis,2008,46(2):E12-E18.
[18] Hoang LM,Maguire JA,Doyle P,et al.Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre(1997-2002):epidemiology,microbiology and histopathology[J].J Med Microbiol,2004,53(Pt 9):935-940.
[19] Zaragoza O,Rodrigues ML,De Jesus M,et al.The capsule of the fungal pathogen Cryptococcus neoformans[J].Adv Appl Microbiol,2009,68:133-216.
[20] Kozel TR,Gotschlich EC.The capsule of Cryptococcus-neoformans passively inhibits phagocytosis of the yeast by macrophages[J].J Immunol,1982,129(4):1675-1680.
[21] Levitz SM,Tabuni A.Binding of Cryptococcus neoformans by human cultured macrophages.Requirements for multiple complement receptors and actin[J].J Clin Invest,1991,87(2):528-535.
[22] Walenkamp AM,Chaka WS,Verheul AF,et al.Cryptococcus neoformans and its cell wall components induce similar cytokine profiles in human peripheral blood mononuclear cells despite differences in structure[J].FEMS Immunol Med Microbiol,1999,26(3-4):309-318.
[23] Vecchiarelli A,Retini C,Monari C,et al.Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes[J].Infect Immun,1996,64(7):2846-2849.
[24] Moyrand F,Fontaine T,Janbon G.Systematic capsule gene disruption reveals the central role of galactose metabolism on Cryptococcus neoformans virulence[J].Mol Microbiol,2007,64(3):771-781.
[25] Pietrella D,Lupo P,Bistoni F,et al.An early imbalance of interleukin 12 influences the adjuvant effect of mannoproteins of Cryptococcus neoformans[J].Cell Microbiol,2004,6(9):883-891.
[26] Orendi JM,Verheul AF,De Vos NM,et al.Mannoproteins of Cryptococcus neoformans induce proliferative response in human peripheral blood mononuclear cells (PBMC) and enhance HIV-1 replication[J].Clin Exp Immunol,1997,107(2):293-299.
[27] Kozel TR,Gotschlich EC.The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages[J].J Immunol,1982,129(4):1675-1680.
[28] Kozel TR,Highison B,Stratton CJ.Localization on encapsulated Cryptococcus neoformans of serum components opsonic for phagocytosis by macrophages and neutrophils[J].Infect Immun,1984,43(2):574-579.
[29] Shao X,Mednick A,Alvarez M,et al.An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia[J].J Immunol,175(5):3244-3251.
[30] Tucker SC,Casadevall A.Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm[J].Proc Natl Acad Sci USA,2002,99(5):3165-3170.
[31] Alvarez M,Casadevall A.Cell-to-cell spread and massive vacuole formation after Cryptococcus neoformans infection of murine macrophages[J].BMC Immunol,2007,8:16.
[32] Bach MC,Tally PW,Godofsky EW.Use of cerebrospinal fluid shunts in patients having acquired immunodeficiency syndrome with cryptococcal meningitis and uncontrollable intracranial hypertension[J].Neurosurgery,1997,41(6):1280-1282.
[33] Banerjee U,Gupta K,Venugopal P.A case of prosthetic valve endocarditis caused by Cryptococcus neoformans var.neoformans[J].J Med Vet Mycol,1997,35(2):139-141.
[34] Walsh TJ,Schlegel R,Moody MM,et al.Ventriculoatrial shunt infection due to Cryptococcus neoformans:an ultrastructural and quantitative microbiological study[J].Neurosurgery,1986,18(6):373-375.
[35] Lei G,Chen M,Li H,et al.Biofilm from a clinical strain of Cryptococcus neoformans activates the NLRP3 inflammasome[J].Cell Res,2013,23(7):965-968.
[36] Nakamura K,Miyazato A,Xiao G,et al.Deoxynucleic acids from Cryptococcus neoformans activate myeloid dendritic cells via a TLR9-dependent pathway[J].J Immunol,208,180(6):4067-4074. |